tailieunhanh - Báo cáo khoa học: Expression of squamous cell carcinoma antigen-1 in liver enhances the uptake of hepatitis B virus envelope-derived bio-nanocapsules in transgenic rats

We previously developed the bio-nanocapsule, which consists of hepatitis B virus envelope L proteins. The bio-nanocapsule can be used to deliver genes and drugs specifically to the human liver-derived tissues in xenograft models, presumably by utilizing the human liver-specific mechanism of hepatitis B virus infection. | ễFEBS Journal Expression of squamous cell carcinoma antigen-1 in liver enhances the uptake of hepatitis B virus envelope-derived bio-nanocapsules in transgenic rats Takeshi Kasuya1 2 Shintaro Nomura2 Takashi Matsuzaki1 3 Joohee Jung1 3 Tadanori Yamada1 Kenji Tatematsu1 Toshihide Okajima1 Katsuyuki Tanizawa1 2 and Shun ichi Kuroda1 3 1 Department of StructuralMolecular Biology The Institute of Scientific and IndustrialResearch Osaka University Japan 2 Graduate Schoolof Frontier Bioscience Osaka University Japan 3 Japan Science and Technology Agency Kawaguchi Saitama Japan Keywords bio-nanocapsule drug delivery system hepatitis B virus squamous cell carcinoma antigen-1 transgenic rat Correspondence S. Kuroda Department of Structural Molecular Biology The Institute of Scientific and IndustrialResearch Osaka University 8-1 Mihogaoka Ibaraki Osaka 567-0047 Japan Fax 81 6 6879 8462 Tel 81 6 6879 8462 E-mail skuroda@ Present address Institute for Innovative Cancer Research Asan MedicalCenter Seoul Korea Received 22 July 2008 revised 18 September 2008 accepted 22 September 2008 doi We previously developed the bio-nanocapsule which consists of hepatitis B virus envelope L proteins. The bio-nanocapsule can be used to deliver genes and drugs specifically to the human liver-derived tissues in xenograft models presumably by utilizing the human liver-specific mechanism of hepatitis B virus infection. The hepatitis B virus tropism is highly restricted to humans and higher primates. Thus to evaluate the in vivo therapeutic effects of forthcoming bio-nanocapsule-based medicines it will be crucial to develop an animal model whose liver is susceptible to both bio-nanocapsule and hepatitis B virus. In the present study we aimed to establish a bio-nanocapsule-susceptible animal model using transgenic rats expressing squamous cell carcinoma antigen-1 SCCA1 which has been proposed to be a receptor for hepatitis B virus interacting with